Hopace H Capsules contain Ramipril 2.5 mg/5 mg and Hydrochlorothiazide 12.5 mg.

Hopace H Capsules combine the long-acting ACE inhibitor Ramipril with the thiazide diuretic Hydrochlorothiazide to provide complementary blood pressure reduction. Ramipril suppresses the renin-angiotensin-aldosterone system by inhibiting the formation of angiotensin II, while Hydrochlorothiazide promotes sodium and water excretion, reducing plasma volume and peripheral vascular resistance. The combination provides effective once-daily blood pressure control in patients whose hypertension is adequately stabilized on the individual components.

Hopace H Capsules are indicated for the treatment of mild to moderate hypertension in patients for whom combination therapy is appropriate and who have been stabilized on the individual components administered in the same proportions.

Ramipril is a long-acting angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, resulting in reduced vasoconstriction, decreased aldosterone secretion, and lower blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal renal tubules, increasing urinary excretion of sodium, chloride, and water. Natriuresis may be accompanied by potassium and bicarbonate loss, while Hydrochlorothiazide helps offset the hyperkalaemia that may occur with Ramipril therapy.

The recommended initial dosage is one capsule orally once daily. If necessary, the dose may be gradually increased to achieve target blood pressure. The maximum recommended daily dose is Ramipril 10 mg and Hydrochlorothiazide 25 mg, or as directed by the physician.

Hopace H Capsules are contraindicated in patients with anuria, known hypersensitivity to Ramipril, Hydrochlorothiazide, or any component of the formulation, history of angioedema, unilateral or bilateral renal artery stenosis, severe hepatic impairment, and during the second and third trimesters of pregnancy.